U.S. Gas Utilities Stock News

NYSE:FDP
NYSE:FDPFood

Fresh Del Monte Produce (FDP) Earnings Hit One Off Loss That Fuels Margin Debate

Fresh Del Monte Produce (FDP) has reported a mixed set of FY 2025 numbers, with Q3 revenue of US$1.0b and a basic EPS loss of US$0.61, set against trailing 12 month EPS of US$1.65 and net income of US$79.2m. The company has seen quarterly revenue move between US$1.0b and US$1.2b over the last six reported periods, while basic EPS has ranged from a loss of US$0.61 to a high of US$1.18. The latest quarter therefore lands at the weaker end of that spectrum and leaves investors focused on how...
NYSE:CHE
NYSE:CHEHealthcare

Assessing Chemed (CHE) Valuation After New US$300 Million Buyback And Ongoing Dividend Streak

Chemed (CHE) has put shareholder returns back in focus after boosting its equity buyback authorization by US$300 million and reaffirming a US$0.60 quarterly dividend, maintaining a long running payout record. See our latest analysis for Chemed. Those buyback and dividend decisions come after a solid 90 day share price return of 8.93% and a 10.35% year to date share price gain, even though the 1 year total shareholder return is 15.45% lower. This suggests that recent momentum contrasts with...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

Is It Time To Reassess CoreWeave (CRWV) After AI Infrastructure Backlog Headlines?

If you are asking yourself whether CoreWeave is fairly priced at its current level, this article will walk you through what the numbers suggest about that question. The stock recently closed at US$95.45, with a 0.3% return over 7 days, a 5.7% decline over 30 days and a 20.3% gain year to date. These moves may signal changing views on both its growth potential and risk. Recent headlines have focused on CoreWeave's position in AI infrastructure and cloud services, as investors continue to...
NYSE:AWR
NYSE:AWRWater Utilities

How Investors May Respond To American States Water (AWR) Earnings, Dividend Hike, And Infrastructure Spending Plan

In the past week, American States Water Company reported fourth-quarter 2025 sales of US$164.28 million and net income of US$28.74 million, alongside full-year 2025 revenue of US$658.07 million and earnings per share of US$3.37 from continuing operations. The company paired this steady profit performance with another quarterly dividend increase to US$0.5040 per share and plans for substantial, regulator-supported infrastructure investment, underscoring its focus on long-term capital...
NasdaqGS:LCID
NasdaqGS:LCIDAuto

Lucid Group Leans Into Autonomous Software Partnerships As Fleet Risks Mount

Lucid Group (NasdaqGS:LCID) is shifting its long term focus toward software and autonomous driving partnerships, aiming to prioritize software and AI development over pure vehicle sales. The company has entered a major partnership with Uber and Nuro to deploy a large fleet of autonomous premium EVs, supported by a substantial investment from Uber. Lucid is making several high level executive appointments to strengthen global supply chain and engineering leadership as it works to execute this...
NasdaqGS:ASTS
NasdaqGS:ASTSTelecom

Assessing AST SpaceMobile (ASTS) Valuation After Convertible Notes Deal And BlueBird 6 Milestone

AST SpaceMobile (ASTS) has put two big issues on the table at once: a US$1b low coupon convertible notes deal that reshapes its capital structure, and the successful deployment of its BlueBird 6 satellite. See our latest analysis for AST SpaceMobile. Those financing moves and the BlueBird 6 deployment come after a volatile run, with a 66.53% 3 month share price return and a very large 3 year total shareholder return of about 13x. However, recent 1 month and 7 day share price declines suggest...
NasdaqGS:RVMD
NasdaqGS:RVMDBiotechs

Is Revolution Medicines (RVMD) Pricing In Pipeline Progress After A 135.7% One Year Surge?

If you are wondering whether Revolution Medicines at around US$99.79 is priced for its future potential or getting ahead of itself, you are in the right place for a clear look at what the current valuation is really telling you. The stock has had a mixed run recently, with a 1.8% gain over the last 7 days, a 17.0% decline over the past month, a 26.3% year to date return, and 135.7% over the last year, along with a very large 3 year return that sits just under 3x. These moves sit against a...
NYSE:ASGN
NYSE:ASGNIT

Assessing ASGN (ASGN) Valuation After Federal Leadership Move And New Cloud FinOps Partnership

ASGN (ASGN) has returned to focus after appointing federal services veteran Donnie Scott to lead its Federal Segment and announcing a new cloud FinOps partnership between Apex Systems and Cloudaware targeting enterprise cost management needs. See our latest analysis for ASGN. The latest management changes and cloud partnership arrive as ASGN’s 1-day share price return of 4.53% contrasts with a 30-day share price return decline of 11.95% and a 1-year total shareholder return loss of 40.56%...
NYSE:AVA
NYSE:AVAIntegrated Utilities

Assessing Avista (AVA) Valuation After Idaho Electricity Rate Increase Request

Idaho rate case puts Avista (AVA) in focus Avista (AVA) has filed for an annual electric rate adjustment with the Idaho Public Utilities Commission, seeking a 7.4% revenue increase tied to funding electric energy efficiency programs. See our latest analysis for Avista. Avista’s recent Idaho rate case comes as the stock’s share price return is up 4.95% over 30 days and 8.91% year to date, while its 1 year total shareholder return of 18.58% points to steady, if moderate, momentum rather than a...
NYSE:KSS
NYSE:KSSMultiline Retail

Did Kohl’s New Under‑$10 “Deal Bar” Just Shift Kohl's (KSS) Investment Narrative?

Kohl’s recently introduced a new “Deal Bar” section at the front of all its stores, offering gifts, seasonal items, and everyday essentials priced at US$10 or less to appeal to cost-conscious shoppers. This move underlines Kohl’s push to revive store traffic by foregrounding sharply priced impulse and necessity purchases as consumers trim discretionary spending. Next, we’ll examine how the new under-US$10 Deal Bar concept could influence Kohl’s turnaround-focused investment narrative and...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Why Rivian (RIVN) Is Up 15.4% After Mixed Q4 Results And A VW-Funded Tech Pivot

Rivian Automotive reported fourth-quarter 2025 revenue of US$1,286 million, down from US$1,734 million a year earlier, with a net loss of US$811 million, while full-year revenue rose to US$5,387 million and the annual net loss narrowed to US$3,646 million. Alongside these results, Rivian filed a US$1.10 billion shelf registration for ESOP-related Class A shares and highlighted growing software revenue and funding from its Volkswagen joint venture, underscoring its shift toward a technology...
NasdaqGS:ON
NasdaqGS:ONSemiconductor

How Weaker Results And All-Free-Cash-Flow Buybacks At ON (ON) Have Changed Its Investment Story

In February 2026, ON Semiconductor reported fourth-quarter 2025 sales of US$1,530.1 million and net income of US$181.8 million, while full-year 2025 sales reached US$5,995.4 million with net income of US$121 million, alongside first-quarter 2026 guidance for revenue of US$1,435 million to US$1,535 million and diluted EPS of US$0.28 to US$0.38. At the same time, the company underscored growing AI data center demand, stabilization in automotive and industrial markets, and a commitment to...
NYSE:HIMS
NYSE:HIMSHealthcare

Is Hims & Hers Health (HIMS) Now Attractive After Sharp Share Price Pullback?

If you are wondering whether Hims & Hers Health at around US$15.84 is starting to look attractive, you are not alone in asking what the current price really gets you. The share price has pulled back sharply, with a 5.1% decline over the last 7 days, a 49.5% decline over the last 30 days, and a 52.6% decline year to date, even though the 3 year return sits at 70.5%. Over the past year, the stock has also recorded a 77.0% decline, and the 5 year return stands at a 5.9% decline, which has...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Is FDA and Reimbursement Momentum Altering The Investment Case For Guardant Health (GH)?

In the days leading up to its recent earnings release, Guardant Health, a liquid biopsy specialist, drew increased attention after previously reporting US$265.2 million in quarterly revenue, up strongly year on year and ahead of analyst expectations. Institutional investors have been highlighting Guardant Health’s progress on FDA submissions, reimbursement expansion, and margin improvement, which together suggest meaningful operational momentum despite ongoing concerns about scale and...
NYSE:SHW
NYSE:SHWChemicals

Sherwin-Williams Labor Lawsuit Tests Employment Practices And Investor Risk Outlook

Sherwin-Williams (NYSE:SHW) is facing a new class action lawsuit in California. The suit alleges violations of labor laws, including unpaid minimum and overtime wages. Claims also include denial of required meal and rest breaks and related wage and hour issues. The case raises questions about employment practices and potential legal liabilities for the company. Sherwin-Williams, a major paints and coatings producer, is closely tied to housing, construction, and maintenance activity. Many...
NYSE:PLD
NYSE:PLDIndustrial REITs

Assessing Prologis (PLD) Valuation After Toxic Gas Verdict And Growing Legal Liabilities

A recent Los Angeles jury verdict tied to toxic hydrogen sulfide gas exposure at a Prologis (PLD) warehouse has put the company’s legal risks in focus, with multimillion dollar damages and thousands of related claims pending. See our latest analysis for Prologis. At a share price of $139.63, Prologis has seen a 13.41% 90 day share price return and an 18.89% 1 year total shareholder return, suggesting positive momentum as the recent legal verdict and a 6% dividend increase reshape how...
NYSE:AES
NYSE:AESRenewable Energy

Is It Too Late To Consider AES (AES) After A 66% One Year Rally?

Wondering if AES at US$16.29 is still offering value after its recent run, or if the easy money has already been made? This article is here to help you size that up calmly and clearly. The stock has returned 14.8% over the last 30 days and 65.6% over the last year, while the 3-year and 5-year returns of 26.4% and 29.7% declines show that the longer term picture has been very different. Recent news flow around AES has focused on its position in US utilities, including how investors are...
NYSE:WKC
NYSE:WKCOil and Gas

Will Recurring EPS Misses And A 2026 CEO Shift Change World Kinect's (WKC) Narrative

World Kinect Corporation recently reported Q4 EPS of US$0.54, missing analyst estimates by 11% for a third straight quarter amid ongoing margin pressure and revenue declines, while confirming that CFO and President Ira Birns will take over as CEO from 1 January 2026. This combination of recurring earnings disappointments, leadership change, and management’s interest in acquisitions to support EPS has sharpened questions about the company’s ability to rely on its core operations for future...
NYSE:IMAX
NYSE:IMAXEntertainment

IMAX (IMAX) Valuation Check As Exclusive Elvis And Tommy Events Draw Premium Cinema Fans

IMAX (IMAX) is back in the spotlight as it prepares an exclusive theatrical debut for Baz Luhrmann’s Elvis Presley concert documentary, alongside two-day 50th anniversary IMAX screenings of The Who’s rock opera film Tommy. See our latest analysis for IMAX. At a share price of US$37.80, IMAX has logged a 6.78% 3 month share price return and a 38.87% 1 year total shareholder return, and recent box office events and premium content partnerships appear to be contributing to gradually building...
NasdaqGS:VNOM
NasdaqGS:VNOMOil and Gas

Viper Energy Refocuses On Permian Royalties As Valuation Debate Grows

Viper Energy (NasdaqGS:VNOM) is acquiring Sitio Royalties, expanding its royalty footprint in US shale. The company plans to sell its non Permian assets, sharpening its focus on its core basin. Management is working on integrating Sitio's assets into Viper's no capex royalty model. Analysts are highlighting how the combined royalty portfolio could affect future cash generation and distributions. Viper Energy, trading at $44.61, has seen its share price move 20.8% over the past month and...
NYSE:TMO
NYSE:TMOLife Sciences

Is Thermo Fisher’s Datavant Deal and Clario Financing Altering The Investment Case For TMO?

Earlier in February 2026, Thermo Fisher Scientific’s PPD clinical research business announced a data collaboration with Datavant and completed a US$3.80 billions multi‑tranche senior notes offering, largely to help fund its pending acquisition of Clario Holdings. This combination of enhanced real‑world data capabilities and fresh long-term financing underscores how Thermo Fisher is reinforcing its position across clinical research and evidence generation. Next, we’ll examine how integrating...
NasdaqGS:AMAT
NasdaqGS:AMATSemiconductor

Applied Materials (AMAT) Is Up 8.7% After Strong Q1 Results And Major AI-Focused Expansion Moves

Applied Materials, Inc. recently reported fiscal Q1 2026 results showing sales of US$7,012 million and net income of US$2,026 million, while also settling a US$252.5 million export-control matter with the U.S. Department of Commerce and receiving no-action closures from the Department of Justice and SEC. At the same time, the company is leaning into the AI infrastructure buildout with new 2nm-and-beyond chipmaking tools, a US$5.00 billion EPIC R&D center joined by Samsung, and guidance for...
NYSE:CRH
NYSE:CRHBasic Materials

How Earnings Beat, Higher Dividend And New Buyback Will Impact CRH (CRH) Investors

CRH plc has reported its fourth-quarter and full-year 2025 results, with revenue of US$9,416 million and net income of US$1,025 million in Q4, alongside a 5% increase in the quarterly dividend to US$0.39 per ordinary share and the completion of a large share buyback phase totaling 77,073,466 shares since 2023. Alongside filing its 2025 Annual Report, CRH issued 2026 guidance for net income of US$3.90 billion to US$4.10 billion and diluted EPS of US$5.60 to US$6.05, while launching a new...
NasdaqGS:HOOD
NasdaqGS:HOODCapital Markets

Reassessing Robinhood (HOOD) After Sharp Pullback And Elevated P/E Valuation

If you are trying to figure out whether Robinhood Markets' current share price lines up with its underlying worth, you are in the right place. The stock recently closed at US$75.21, with a 3.5% decline over the last 7 days, a 30.8% decline over 30 days, a 34.7% decline year to date, a 27.0% return over 1 year and a very large positive return over 3 years. Recent headlines around Robinhood have focused on its role in retail trading, regulatory attention on trading platforms and the continued...